A year-long randomized controlled trial found that older adults with overweight or obesity who took higher doses of vitamin D3 experienced modest drops in blood pressure compared to those on lower doses. The double-blind study enrolled 221 ambulatory older adults and compared daily vitamin D3 at roughly 600 IU against roughly 3,750 IU, with calcium provided to both groups. The findings add new evidence to a long-running debate about whether vitamin D can meaningfully affect cardiovascular risk factors, but they also sit alongside earlier trials that found no such benefit.
Why blood pressure changes from vitamin D matter for older adults
Millions of older adults already take vitamin D supplements for bone health, and any secondary benefit for blood pressure would change how clinicians weigh the value of higher doses. The trial behind these findings, conducted in Beirut and published in the Journal of the Endocrine Society, specifically targeted people who were both elderly and overweight, a population at elevated risk for hypertension and metabolic disease. Both systolic and diastolic readings declined more in the group receiving roughly 3,750 IU per day than in the group receiving roughly 600 IU per day over the 12-month study period.
One hypothesis worth testing is whether the blood pressure benefit observed in this population works through improved insulin sensitivity rather than through direct effects on blood vessels. The same Beirut-based cohort that produced the blood pressure paper also generated a separate publication examining vitamin D replacement and indexes of insulin resistance. If the blood pressure reductions were driven primarily by metabolic improvements, researchers would expect the largest drops in participants who also showed the greatest decline in HOMA-IR, a standard measure of insulin resistance. The available publications from this trial do not report a direct mediation analysis linking HOMA-IR changes to blood pressure changes, which leaves this mechanism plausible but unconfirmed.
That distinction matters for clinical practice. A metabolically mediated blood pressure effect would apply mainly to patients with insulin resistance, not to lean older adults or those with normal glucose metabolism. A direct vascular effect, by contrast, could benefit a broader range of people. Without clear evidence separating the two pathways, clinicians cannot yet tailor vitamin D dosing recommendations based on a patient’s metabolic profile.
Another practical concern is safety. Higher vitamin D doses can raise calcium levels and, in theory, increase the risk of kidney stones or vascular calcification, especially when combined with calcium supplements. The Beirut trial reported that both doses were generally well tolerated over one year, but longer-term safety in real-world populations, who may take other medications and have comorbid conditions, remains less certain. Clinicians must therefore balance the possibility of small blood pressure improvements against the need to avoid excessive cumulative vitamin D and calcium exposure.
Competing trial results and what the pooled data show
The Beirut trial did not produce its findings in isolation. It was pre-registered on ClinicalTrials.gov under the identifier NCT01315366, with the formal title “Hypovitaminosis D: A Link Between Bone/Mineral and Fat/Fuel Metabolism.” The trial used dosing of 600 IU per day versus roughly 3,750 IU per day across its 221 participants, with calcium co-supplementation built into both arms. Participants were ambulatory, community-dwelling older adults with overweight or obesity, and the study aimed to correct low vitamin D status while tracking multiple metabolic and cardiovascular outcomes.
Set against these results, the BEST-D trial, a separate randomized placebo-controlled study in community-dwelling older adults, tested daily vitamin D at 2,000 IU or 4,000 IU versus placebo for 12 months and reported no significant blood pressure effect. The BEST-D study also measured arterial stiffness and cardiac function, finding no meaningful changes. The contrast between these two trials is instructive: the Beirut cohort was specifically selected for overweight and obesity, while BEST-D enrolled a broader community-dwelling population. Body composition and baseline metabolic health may explain why one trial detected a modest effect and the other did not.
A systematic review and meta-analysis pooling randomized controlled trial evidence on vitamin D supplementation and blood pressure in elderly populations found that when effects do appear, they tend to be small in magnitude. This is the basis for describing the Beirut trial’s results as “modest.” The pooled analysis also identified significant variation across studies depending on participants’ baseline blood pressure levels and their starting vitamin D status, measured by 25-hydroxyvitamin D concentrations. Participants who began with lower vitamin D levels and higher blood pressure tended to show larger responses.
That pattern aligns with a dose-response logic: correcting a genuine deficiency may produce measurable physiological changes, while supplementing someone who already has adequate vitamin D levels is less likely to move the needle. The BEST-D trial did not restrict enrollment to vitamin D–deficient participants, which could partly explain its null result. In contrast, the Beirut investigators focused on individuals with low vitamin D and excess adiposity, two factors that may amplify the impact of supplementation on blood pressure and metabolic markers.
Even in studies that do show a benefit, the absolute reductions in systolic and diastolic pressure are usually only a few millimeters of mercury. For an individual patient, such a change may not be enough to avoid antihypertensive medication or to meaningfully lower short-term cardiovascular risk. At the population level, however, small average reductions in blood pressure can translate into fewer strokes and heart attacks, particularly in older adults who already face elevated baseline risk.
Open questions about dose, duration, and who benefits
Several gaps in the evidence prevent firm conclusions. The Beirut trial enrolled 221 participants, a sample size large enough to detect group-level trends but too small to reliably identify which subgroups benefited most. The exact millimeters of mercury by which systolic and diastolic pressure declined in the higher-dose group are reported in the primary paper, but the effect sizes from the full text have not been widely extracted into the secondary literature, making independent verification of the clinical significance more difficult for clinicians who rely on summaries and guidelines.
Another open question is whether the observed blood pressure changes would persist beyond one year or plateau over time. Vitamin D status can fluctuate with season, diet, and adherence, and older adults often adjust or discontinue supplements without medical supervision. Long-term extension studies would be needed to determine whether maintaining higher vitamin D levels continues to confer any incremental blood pressure benefit or whether the effect is largely front-loaded during the correction of deficiency.
Optimal dosing also remains unsettled. The Beirut trial compared roughly 600 IU and 3,750 IU, while BEST-D tested 2,000 IU and 4,000 IU against placebo. None of these studies establish a clear threshold above which additional vitamin D offers no further blood pressure improvement, nor do they define a minimal effective dose for hypertensive or pre-hypertensive older adults with deficiency. Given the narrow margin between modest benefit and potential toxicity at very high intakes, future trials will need to explore intermediate doses and stratify participants by baseline vitamin D levels.
Patient selection may ultimately be as important as dose. The existing evidence suggests that older adults with obesity, low vitamin D status, and elevated blood pressure are the most likely to see any reduction from supplementation. By contrast, lean individuals with normal baseline levels and well-controlled blood pressure appear unlikely to benefit in this domain, even if they take higher doses. Incorporating baseline 25-hydroxyvitamin D testing and careful blood pressure monitoring into trial designs could clarify which clinical profiles predict a response.
For now, the practical takeaway is cautious and conditional. Vitamin D supplementation remains appropriate for older adults at risk of deficiency, particularly for bone and muscle health, and the possibility of a small blood pressure benefit in select high-risk groups is a reasonable secondary consideration. However, the current data do not support using high-dose vitamin D as a stand-alone antihypertensive therapy or as a universal strategy for cardiovascular prevention. Clinicians and patients should view vitamin D as one piece of a broader risk-reduction toolkit that still relies primarily on lifestyle changes and established blood pressure–lowering medications.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
